It feels intuitive that anything insurance covers must be the best option — and anything insurance doesn’t cover must be experimental or fringe. The reality is more complicated, and worth understanding.
How insurance coverage decisions actually work
Insurance covers what has been established long enough to get coded, approved, and reimbursed through the system. That process takes years. Sometimes decades. By the time something becomes routinely covered, the science behind it has often been settled for a long time — and may have already been refined or surpassed by approaches that haven’t completed the same multi-year administrative process yet.
This is not a conspiracy. It’s how a slow-moving system designed for cost control and risk management works. But it has implications for patients evaluating their options.
Cortisone: covered, with documented limitations
Corticosteroid joint injections are fully covered by most insurance plans. They’ve been part of standard orthopedic care for decades.
Meanwhile, the research on repeated cortisone injections has been clear for years that, with chronic use, they may accelerate joint degeneration. The 2020 Radiology study and follow-up work made this finding visible. The science moved. The coverage didn’t. Cortisone remains routinely covered, and routinely administered, even where the long-term picture has been called into question.
Hyaluronic acid: covered for years, then partially uncovered
Hyaluronic acid injections were covered by most insurance plans for years. Then a systematic review of the literature found that hyaluronic acid performed no better than saline placebo in many of the joint applications it was being used for.
Many insurers eventually pulled coverage. But that pullback happened long after the science had shifted — patients had been receiving covered injections for years that the literature had already called into question. The coverage system didn’t catch up to the evidence quickly.
Why current regenerative options are typically cash-based
The most current, evidence-supported regenerative options — allogeneic structural tissues, combination protocols, exosome products — are predominantly cash-based today. Not because they haven’t been studied. Many have been studied extensively, with peer-reviewed publications behind them. They’re cash-based because they haven’t completed the multi-year insurance coding and reimbursement process yet.
This distinction matters. Cash-based does not automatically equal experimental. Insurance-covered does not automatically equal current.
The principle this points to
Insurance coverage is not a reliable proxy for clinical quality or current evidence. It’s a reflection of administrative processes that move on a different timeline than clinical research.
The question worth asking your provider isn’t simply “What does my insurance cover?” — although that’s a fair financial question. The more useful clinical question is: “What is the most current, evidence-supported approach for what I have, and what are the trade-offs?”
Those may be different answers.
What cash-pay should and shouldn’t mean
We’re a cash-pay regenerative practice, and we’re honest about that with every patient. Cash-pay isn’t a feature. It’s a structural reality of where the most current options sit in the reimbursement landscape today.
What cash-pay should mean for patients: complete transparency about what’s being recommended and why, the ability to spend the time a thorough consultation actually takes, freedom to recommend the protocol that fits the patient’s biology rather than the protocol that fits a coding requirement.
What cash-pay should never mean: pressure, opacity, or recommendations that don’t fit the actual structural picture. Those are warning signs in any clinical setting, regardless of payment model.
How to evaluate options across both worlds
A reasonable approach for any patient: understand what insurance will cover and consider it on its merits. Understand what cash-based options exist and consider them on their merits. Don’t assume the first category is automatically best. Don’t assume the second is automatically better either.
Ask for the evidence. Ask for the trade-offs. Ask what the protocol is supposed to do biologically and how that maps to your specific structural picture. The answers tell you what you need to know — regardless of who’s paying.
REQUIRED DISCLAIMER
Educational content only. The information presented in this article is for general informational and educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. RegenHaus uses 361 HCT/P regenerative biologics, which are not FDA-approved to treat or cure any condition. Individual results vary. Please consult a licensed medical provider before considering any therapy or making changes to your health regimen.
